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Summary
The prognostication of head and neck squamous cell carcinoma (HNSCC) is largely based upon the tumor size and location
and the presence of lymph node metastases. Here we show that gene expression patterns from 60 HNSCC samples
assayed on cDNA microarrays allowed categorization of these tumors into four distinct subtypes. These subtypes showed
statistically significant differences in recurrence-free survival and included a subtype with a possible EGFR-pathway
signature, a mesenchymal-enriched subtype, a normal epithelium-like subtype, and a subtype with high levels of antioxidant
enzymes. Supervised analyses to predict lymph node metastasis status were approximately 80% accurate when tumor
subsite and pathological node status were considered simultaneously. This work represents an important step toward the
identification of clinically significant biomarkers for HNSCC.
Introduction within the first two years (Jones et al., 1992; Takes et al., 1997).
Most of the clinical decisions regarding therapy are commonly
based upon clinical staging, which relies on nodal status andTumors of head and neck, which include the upper aerodigestive
tract (oral cavity, oropharynx, hypopharynx, and larynx), account tumor size. No biomarkers analogous to the estrogen receptor
or HER2 in breast cancers, or c-KIT in gastrointestinal stromalfor over 40,000 cases of cancer per year in the US (Jemal et
al., 2002; Landis et al., 1999). The most common histology of tumors, exist for HNSCC patients, suggesting that genomic
profiling studies may be useful for identifying new biomarkershead and neck tumor is squamous cell carcinoma. The main
prognostic variables of head and neck squamous cell carcinoma with prognostic or predictive value.
Gene expression analyses have proven to be a useful tool(HNSCC) are the location and size of the tumor, the presence
of distant metastasis, and the presence of cervical lymph node for the classification of human solid tumors arising from a single
organ site (Garber et al., 2001; Huang et al., 2003; Perou et al.,(LN) metastasis (Andersen et al., 1994; Sessions et al., 2002).
About 40%–50% of patients with advanced disease (Stage III 2000) or from different sites (Ramaswamy et al., 2001). These
organ site-specific studies have typically subclassified tumorsand IV) recur, and approximately 80% of recurrences occur
S I G N I F I C A N C E
Despite the aggressive multimodality treatment of HNSCC patients with surgery, chemotherapy, and radiation therapy, approximately
40%–50% of patients with advanced disease recur. To date, there are no reliable biomarkers to predict who will have poor clinical
outcome. In this study, we identified four distinct subtypes of HNSCC tumors based upon patterns of gene expression that showed
clinically distinct behaviors and which showed different patterns of EGFR pathway activation, even within EGFR-expressing tumors.
This finding could prove important for the selection of patients for treatment with EGFR inhibitors. In addition, we identified an expression
signature that could predict the presence of lymph node metastases using the primary tumor from the time of diagnosis. If these
data can be validated on independent cohorts, then these gene expression patterns will provide valuable information that can be
used to assist in treatment decisions for HNSCC.
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into relatively homogenous groups based upon their gene ex- Table 1. Overall clinical characteristics of HNSCC patients
pression patterns and have shown that these groupings can
Age
predict clinical outcomes (Alizadeh et al., 2000; Bhattacharjee
Median (range) 56 yr (30–77)et al., 2001; Dhanasekaran et al., 2001; Garber et al., 2001;
40 4 (7%)Sorlie et al., 2001). Furthermore, lymph node metastasis status
40 56 (93%)
can sometimes be predicted from the gene expression patterns
Sexof primary tumors (Huang et al., 2003; MacDonald et al., 2001),
Male 53 (88%)which could spare many patients from unnecessary lymph node
Female 7 (12%)dissections. Here we have analyzed the gene expression pat-
Ethnicityterns of 60 HNSCC tumors and identified distinct subtypes of
HNSCC with different clinical outcomes. Many of the patterns White 37 (62%)
Black 18 (30%)identified in this study have also been seen in other tumor stud-
Others 5 (8%)ies focused on breast and lung carcinomas (Garber et al., 2001;
Perou et al., 2000), and some have been seen in other airway Tobacco use
epithelial studies (Ha et al., 2003; Hackett et al., 2003). In addi- Yes 58 (97%)
tion, we were able to identify patterns of expression that could No 2 (3%)
predict the presence of LN metastases in HNSCC tumors using Alcohol use
profiles that have been shown to be involved in metastasis
Yes 51 (85%)predictions in breast cancers (Huang et al., 2003; van ’t Veer
No 9 (15%)
et al., 2002). These common patterns suggest that tumors from
Tumor sites in head and neckdifferent sites may share similar cells of origin or common path-
Oral cavity 15 (25%)ways for tumorigenesis and metastasis.
Oropharynx 14 (23%)
Hypopharynx 7 (12%)
Results Larynx 24 (40%)
Clinical StageClass discovery for HNSCC
I-II 11 (18%)Sixty HNSCC samples were assayed using Agilent cDNA mi-
III 14 (23%)croarrays containing 12,814 human genes. Patient demograph-
IV 35 (58%)
ics are presented in Table 1 and the individual patient/tumor
Clinical cervical lymph node metastasischaracteristics are presented in Supplemental Table S1 (see
Positive 33 (55%)http://www.cancercell.org/cgi/content/full/5/5/489/DC1;
Negative 27 (45%)http://dragon.med.unc.edu/pubsup/HN/). To characterize the
Pathological cervical lymph node metastasisdiversity of HNSCC tumors, we performed an “intrinsic” analysis
and identified 582 cDNA clones whose expression optimally Positive 26 (43%)
reflected patterns of expression intrinsic to the tumors (Bhatta- Negative 14 (23%)
Unknown 20 (33%)charjee et al., 2001; Garber et al., 2001; Perou et al., 2000;
Sorlie et al., 2003). Using this gene set, we analyzed 74 samples Pathological differentiation
in a two-way average-linkage hierarchical clustering analysis Well 10 (17%)
(Figure 1 and see Supplemental Figure S1 for the complete Moderate 39 (65%)
Poor 11 (18%)cluster diagram). The cluster analysis identified at least four
groups/subtypes within the 60 tumors based upon the sample
associated cluster dendrogram (Figure 1B), which were desig-
nated as Groups 1 through 4 based on the dendrogram
branches. As expected, all 11 intrinsic pairs used for this analysis subtype (Figure 1E) contained genes involved in desmosome
were closely grouped together on terminal branches of the clus- function (Desmocollin 2, Desmoglein 3, and Cytokeratin 14) and
ter associated sample dendrogram. a homeobox gene that has been implicated in controlling the
The subtype of tumors on the far left (Group 1, red dendro- expression of cell adhesion molecules (BarH-like homeobox 2)
gram branch) showed the highest expression of the genes in (Edelman et al., 2000). Immunohistochemical (IHC) analysis of
Figures 1C and 1E. Contained within Figure 1C were the genes these tumors for gene products from Figure 1E showed that all
for Bullous Pemphigoid Antigen 1, P-Cadherin, Laminin  2, 16 tested had high expression of Cytokeratin 14 and 14/16 were
Collagen XVII-, and two other Laminin subunits ( 3 and  2). positive for Desmoglein 3 (Figures 2E and 2F), while the other
These first four genes are also present in the gene set that tumor subtypes showed much less consistent expression of
define the breast “basal-like” tumor subtype (Perou et al., 2000), these proteins (Figure 2G).
which is a group of breast tumors that display basal-epithelial It is well known that the epidermal growth factor receptor
cell characteristics and show poor patient outcomes (Sorlie et (EGFR) pathway is important for HNSCC (Endo et al., 2000;
al., 2001, 2003). The Figures 1C and 1E patterns also share Grandis, 1998). The gene set in Figure 1E contained at least
significant expression similarity with the lung squamous carci- three genes from this pathway including TGF, FGF-BP, and
noma pattern of Garber et al. (2001), which showed high expres- MMK6. TGF is a ligand for EGFR and a critical activator of
sion of Bullous Pemphigoid Antigen 1, Collagen XVII-, FGF- the EGFR pathway in HNSCC (Endo et al., 2000; Grandis, 1998).
FGF-BP is a promoter of angiogenesis that is induced by EGFBP, and Kallikrein 10. The other defining gene set for this tumor
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in vitro and induced by the ectopic expression of MMK6, which groups, or that Group 4 subtype patients were current and
active smokers.is a MAP kinase kinase that can be downstream of EGFR (Harris
et al., 2000). Among the 60 tumors that were analyzed by To assess the significance of the overlaps between our data
and the selected gene lists described from other studies, wemicroarray, 56 were also analyzed by immunohistochemistry
(IHC) for the presence of EGFR and for the Tyr-1173 phosphory- performed a “simulation analysis” to determine the likelihood of
finding this degree of gene overlap by chance (see Experimentallated form of EGFR (see Supplemental Table S1 at http://www.
cancercell.org/cgi/content/full/5/5/489/DC1). Of these 56 tu- Procedures). A simulation was performed by randomly selecting
a set of genes from the entire set of 12,814. The number selectedmors, 54 were positive for EGFR expression and 35/54 of the
EGFR-expressing tumors were also positive for P-Tyr-1173- was set to the number of genes in our subset being tested.
These randomly selected gene sets were then compared withEGFR. Among the Group 1 tumors, all tested were IHC positive
for EGFR and a high percentage (15/19, 79%) were positive for the corresponding published gene set, the overlap determined,
and then the entire process was repeated 10,000 times. In theP-Tyr-1173-EGFR (50% of Group 2, 75% of Group 3, and 38%
of Group 4 tumors were positive for P-Tyr-1173-EGFR). These final step, the actual number of overlapping genes between our
lists and the published lists were compared to the simulateddata suggest that EGFR signaling is typically active in Group 1
and 3 tumors. These data also show that not all EGFR tumors distributions. Using this analysis, we determined that the likeli-
hood of obtaining the six gene overlap between the smoking-have activated EGFR, which is likely influenced by the presence
of ligands like TGF. associated gene set of Hackett et al. (2003) and our intrinsic
gene list was p  0.01, and p  0.0001 if we use just the 21The subtype of tumors on the center dendrogram branch
(Group 2, blue branch) showed the highest expression of the genes present in Figure 1G (which we believe to be the most
appropriate subset to base this calculation upon). We also per-genes in Figure 1F. Many of these genes are typically produced
by fibroblasts/mesenchymal cells including Vimentin, Syndecan formed a “simulation analysis” for the gene subset present in
Figure 1D where we compared this subcluster to the “normal2, Lysyl-oxidase, and four Collagen subunits (Perou et al., 2000).
This subtype also tended to show low expression of the gene versus tumor” list from Ha et al. (2003), which gave p  0.05
for the entire intrinsic list and p  0.0001 if we use the subsetsets that defined the other subtypes, namely the clusters in
Figures 1C, 1D, and especially 1E (Figure 2G). IHC for Vimentin in Figure 1D only.
We also profiled four HNSCC-derived cell lines with theseacross our cohort of tumors identified eight tumors where the
malignant cells were positive for Vimentin staining; of these data displayed to the left of the tumor-associated cluster dia-
gram (Figure 1). The cell line data was included in a separateeight tumors, four (4/19, 21%) were in Group 1 and four (4/12,
33%) were in Group 2 (Figure 2H). In addition, 7/14 of Group cluster analysis and was median centered using both the cell
lines and tumors, while the tumor data presented in Figure 12 tumors were pathologically described as poorly differentiated,
which suggests that this subtype is characterized by either the was median centered using only the tissue samples. This was
done because the cell lines were very different in expressionpresence of fibroblasts and a strong desmoplastic response,
and/or these tumors may have undergone an epithelial to mes- from the tissue samples, and by median centering the cell lines
relative to the tumors, direct comparisons could be more readilyenchymal transition.
The subtype of tumors identified by the pink dendrogram made. When compared directly to the tumors, the cell lines did
not show any of the dominant patterns of gene expression thatbranch (Group 3) contained the three normal tonsillar epithelium
samples and eleven tumors and was defined by the consistent were seen in the tumors, even though these lines were derived
from primary HNSCC samples.expression of the Figure 1D pattern. Figure 1D contains the
genes for Microsomal Glutathione S-Transferase 2, Cytokeratin
15 that identifies the basal cell layer of stratified squamous Correlation of expression subtypes
with clinical parametersepithelia (Figure 2A; Lloyd et al., 1995), and Cytokeratin 4 that
identifies the suprabasal layer of stratified squamous epithelia The median follow-up time on our HNSCC cohort was 16 months.
Because of this relatively short follow-up, we used recurrence-(Figure 2D; van der Velden et al., 1993). These three genes were
recently identified in a microarray study on HNSCC progression free survival (RFS) as our primary endpoint where we define an
“event” as the time to disease relapse or death. In our cohort,and shown to be expressed at lower levels in HNSCC tumors
versus normal epithelium (Ha et al., 2003), which is precisely there were 18 patients who either died or had a recurrence. We
first examined our intrinsic subtypes by univariate modeling forwhat was observed here. Only 6 of the 47 tumors tested for
Cytokeratin 15 expression by IHC were positive; however, 5 of RFS using Cox regression analysis based upon the dendrogram
branching pattern in Figure 1B; we first divided the samplesthese 6 tumors were in Group 3 (Figures 2I and 2J).
The subtype of tumors in the far right dendrogram branch into two subsets based upon the first major dendrogram branch,
which combines Groups 2–4 into a single category versus Group(Group 4, green branch) showed high expression of the genes
in Figure 1G, many of which are antioxidant-induced enzymes 1 (p  0.03). The second logical grouping based upon the
dendrogram has Group 1 and Group 2 as separate entities andthat are involved in xenobiotic metabolism including Glutathione
S-Transferase M3, Thioredoxin Reductase 1, Glutathione Per- combines Groups 3 and 4 in a single category (p  0.017).
Finally, we examined each group separately (p  0.02 for theoxidase 2, Aldo-Keto Reductase 1, and two genes involved in
the pentose phosphate cycle (Transaldolase 1 and Phosphoglu- four groups). Figures 3A and 3B are Kaplan-Meier plots of RFS
curves for the intrinsic subtypes; in Figure 3A we divided theconate Dehydrogenase). These exact same six genes were
recently shown by Hackett et al. (2003) to be more highly ex- samples into Group 1 versus Groups 2–4 as was done above
(log rank p 0.02), and Figure 3B shows Group 1 versus Grouppressed in the epithelium of smokers than nonsmokers. These
data suggest that either these tumors have a more dramatic 2 versus Groups 3 and 4, which gave a log rank p  0.04.
Tumor subsite (hypopharynx versus other 3 sites, p 0.01),and sustained response to cigarette smoke than the other three
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Figure 1. Intrinsic gene set cluster analysis of 60 HNSCC samples
An intrinsic analysis of 11 paired head and neck epithelial samples was performed and identified 582 cDNA clones that were analyzed using a two-way
hierarchical clustering analysis.
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Figure 2. Immunohistochemical analysis of HNSCC samples
Normal tonsillar epithelium (A–D) and HNSCC samples (E–L) were analyzed by IHC for proteins from the intrinsic gene set and from the EGFR pathway.
A: Normal epithelium stained for Cytokeratin 15 showing basal layer staining.
B: Normal epithelium stained for Cytokeratin 14.
C: Normal epithelium stained for Desmoglein 3 showing plasma membrane staining.
D: Normal epithelium stained for Cytokeratin 4 showing suprabasal staining.
E: Tumor HN02-0408B (Group 1) stained for Cytokeratin 14.
F: Tumor HN02-0408B stained for Desmoglein 3.
G: Tumor HN01-0446B (Group 2) stained for Cytokeratin 14.
H: Tumor HN03-0102B (Group 2) stained for Vimentin.
I: Tumor HN02-0478B (Group 3) stained for Cytokeratin 15.
J: Tumor HN02-0493B (Group 3) stained for Cytokeratin 15.
K: Tumor HN02-0408B (Group 1) stained for EGFR.
L: Tumor HN02-0408B stained for the Tyr-1173 phosphorylated EGFR. Magnification for all images was 100	.
Figure 1. (continued)
A: Scaled-down version of the complete cluster diagram (also available as Supplemental Figure S1).
B: Close-up of the experimental sample-associated dendrogram with the intrinsic pair samples identified by the horizontal black lines. Each sample is color-
coded according to its tumor subtype.
C: P-cadherin containing gene cluster.
D: Gene set containing Cytokeratin 15, which is enriched in normal tonsillar epithelium and Group 3 tumors.
E: Gene set containing TGF- and Cytokeratin 14, enriched in Group 1 tumors.
F: Collagen-containing gene set present in Group 2 tumors.
G: Antioxidant and xenobiotic metabolism-related gene set. The genes in red represent genes discussed in the text.
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Table 2. Lymph node metastasis prediction accuracies
PAM KNN-Euclidean
Clinical LN; 55 tumors 58%; 159 genes 60%; 200 genes
Path LN; 38 60%; 2047 genes 57%; 100 genes
Clinical LN No OC; 40 53%; 55 genes 58%; 50 genes
Path LN No OC; 26a 83%; 1548 genes 83%; 500 genes
aAll analyses were conducted using a 10-fold cross validation analysis, ex-
cept for the “Path LN No Oral Cavity” predictor, which was done using a
leave 23% (6) out analysis
3 sites, p  0.027) and our 3-class intrinsic classification (p 
0.04) when using Cox regression analysis and a cutoff of p 
0.05 to determine statistical significance.
Lymph node metastasis prediction
The presence or absence of lymph node metastases is one of
the most important predictors of disease outcome in HNSCC
patients (Andersen et al., 1994). All 55 of the primary tumors
that we analyzed had known clinical lymph node (LN) metastasis
status, and 38 also had pathological LN status (26 LN positive
and 12 LN negative). The five tumors that were recurrence at
the primary sites were excluded from these LN analyses. To
develop a predictor for LN metastasis status, we utilized two
different supervised statistical analyses. Our predictors included
(1) a simple gene selection method coupled to sample predic-
tions made using an Euclidian correlation to the K-Nearest
Neighbors (KNN) of a given sample (K  3) (Dudoit et al., 2002)
and (2) PAM analysis as described by Tibshirani et al. (2002).
Starting with clinical LN status as the supervising parameter,
we obtained a prediction accuracy of 60% (KNN) and 58%
Figure 3. Kaplan-Meier survival analysis analyzed using a log-rank test
(PAM) when performing a 10-fold cross validation analysis (Ta-
The samples were grouped according to the major dendrogram branches ble 2 and see Experimental Procedures). Because clinical LN
presented in Figure 1 and analyzed using recurrence-free survival as the
status can differ when compared to pathological LN status, weendpoint (where an event is either a disease recurrence or death).
also tested pathological LN status as the supervising parameterA: K-M analysis of Group 1 versus Groups 2–4 combined.
B: K-M analysis of Group 1 versus Group 2 versus Groups 3 and 4 combined. and obtained an accuracy of 57% (KNN) and 60% (PAM).
These low accuracies are likely due to the complex nature
of metastasis, which is influenced by biological, temporal, and
anatomical features. In particular, there is some evidence that
age (p  0.05), and histological differentiation (p  0.04) were the different subsites of HNSCC origins can contribute to clinical
also prognostic factors when using Cox regression analysis and differences (Freier et al., 2003; Huang et al., 2002). Therefore,
RFS as the endpoint; however, we did not find any significant we examined the individual sample predictions made by our
associations between the clinical parameters and our intrinsic pathological metastasis predictors and noticed that 7/13 (KNN)
subtypes by way of contingency table analyses. We also exam- and 6/13 (PAM) mistakes were made on the oral cavity-derived
ined what parameters would make the best bivariable model tumors. The observation that approximately half of the mistakes
and determined that the top two models were (1) 3 intrinsic were made on a single subsite suggested that this subsite might
groups (Group 1 versus Group 2 versus Groups 3 and 4) and be distinct from the others, or more heterogeneous, and there-
hypopharynx subsite (p  0.03 and p  0.046, model chi- fore we removed the oral cavity-derived tumors from our analy-
square 10.04, p  0.007) and (2) 3 intrinsic groups and histo- sis and trained a predictor using only the other three subsites
logical differentiation (p  0.04 and p  0.01, model chi- (i.e., oropharynx, hypopharynx, and larynx). When using clinical
square  10.91, p  0.004). This finding is in agreement with node status (minus oral cavity) as supervision, we obtained an
the lack of correlation between our intrinsic classification and accuracy of 53% and 58%; however, when using pathological
the clinical parameter. We also performed SAM (Tusher et al., node status, we obtained an accuracy of 83%. These data suggest
2001) supervised analyses to determine if any tumor subsite of that even though there were no consistent expression differ-
origin showed distinctive expression features and found that ences that differentiated among the subsites, the oral cavity
no subsite showed a distinctive expression pattern (data not samples were different from the other three subsites or were
shown). Due to the small number of deaths in our cohort (15 more heterogeneous than the other subsites when it comes to
deaths), the only parameters that were significant predictors of expression patterns.
In order to visualize the transcriptional complexity of theoverall survival were tumor subsite (hypopharynx versus other
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Figure 4. Hierarchical clustering analysis of the genes that were predictive of the presence or absence of lymph node metastases in HNSCC tumors
The 500 genes that were associated with prediction of pathological nodal status in HNSCC tumors derived from the larynx, hypopharynx, and oropharynx
(no oral cavity tumors) were used in a two-way clustering analysis across the 26 samples. The node-negative samples are labeled in green and the node-
positive samples are labeled in red.
A: Scaled-down version of the complete cluster diagram (also available as Supplemental Figure S2).
B: Close-up of the interferon-regulated gene set.
C: Close-up of the set of genes associated with cell proliferation rates.
metastasis prediction lists that were generated separately dur- clustering analysis on the 26 tumors with pathological node
status and that were not from the oral cavity (Figure 4 and Supple-ing each round of cross validation (CV), we compiled a list of
the 500 genes that were the most frequently occurring across mental Figure S2 at http://www.cancercell.org/cgi/content/full/
5/5/489/DC1). This analysis sorted the samples into approxi-the 10 runs of the cross validation nodal predictors (see Experi-
mental Procedures). We then used this gene set in a hierarchical mately four dendrogram branches and placed 6/8 of the LN(-)
CANCER CELL : MAY 2004 495
A R T I C L E
samples into a common dendrogram branch; the two LN(-) the EGFR pathway. This evidence includes the genes contained
within Figure 1E, which includes a major ligand of EGFR (TGF),samples that sorted to the left branch correspond to the two
that were misclassified using our predictors. These six LN(-) a kinase that is in the downstream signaling cascade of EGFR
(MKK6), and an angiogenic switch molecule induced by EGFsamples were characterized by the high expression of many
genes involved in immune functions (CXCL9, CXCL10, CXCL11, (FGF-BP) (Harris et al., 2000). In addition, 15/19 of the Group
1 subtype tumors tested by IHC were positive for the Tyr-1173HLA-C) and interferon signaling (STAT1, MX1, and ISG15). Re-
cent expression profiling studies of lymph node metastasis sta- phosphorylated form of the EGFR (Figure 2L), which has been
used in the research settings as a marker for activation of EGFRtus in breast cancers also identified genes involved in immune
and interferon functions as being predictive of metastasis status (Heimberger et al., 2002). These data suggest that Group 1
patients should be evaluated for benefits from EGFR inhibitor-(Huang et al., 2003) and demonstrated that the 11 genes shown
in red in Figure 4B were exactly shared between our study and containing treatment regimens.
The expression profiling of breast tumors has also identifiedthe study of Huang et al. (2003); a “simulation analysis” showed
that this degree of overlap is likely significant at the p  0.0001 distinct tumor subtypes that predicted patient outcomes, with
one of the most aggressive subtypes (basal-like) showing thelevel when using the gene subset present in Figure 4B as the
basis for assessing overlap. Caspase 4 was also shared be- high expression of Bullous Pemphigoid Antigen 1, P-Cadherin,
Laminin  2, and Collagen XVII- (Sorlie et al., 2001, 2003), andtween these two studies, and the LN(-) HNSCC samples also
showed high expression of Caspase 1. This surprising similarity with many of these same genes also being highly expressed in
lung squamous carcinomas (Chung et al., 2002; Garber et al.,across different data sets validates the findings of each study
and suggest that immune cell function may play a role in the 2001). The Group 1 subtype was also distinguished by the high
expression of these four genes. In both breast and HNSCC,metastatic process.
As expected, there were also genes whose expression tumors showing the high expression of these four genes showed
poor patient outcomes. These data suggest that either thesetended to be higher in the LN() tumors, especially the tumors
contained within the dendrogram branch near the center that genes are causative of poor outcomes or they are expressed
by a distinct cell type(s) that consistently gives rise to aggressivewas entirely composed of LN() samples. Included in this gene
set were STK6, RFC, MAD2, ECT2, and CENPA (Figure 4C); tumors.
The other three HNSCC subtypes also showed distinct ex-these five genes are of importance because they were present
in the distant recurrence predictor of van’t Veer et al. for breast pression profiles, some of which have been seen in complemen-
tary airway epithelial microarray studies. The Group 2 tumorscancer (van ’t Veer et al., 2002). In the van’t Veer et al. and our
study, the high expression of these genes was seen in the showed a strong mesenchymal cell signature due to the pres-
ence of many fibroblasts and a lack of epithelial expression-tumors that have metastases or that will go on to form distant
metastases. Finally, some of the other genes in Figure 4C are based differentiation features, and some may have even under-
gone an epithelial to mesenchymal transition (Figures 1F, 2G,known proliferation-associated genes including MCM3, MCM7,
and Kinesin-like 5 (Perou et al., 1999, 2000; Sorlie et al., 2001). and 2H). The Group 3 tumors contained the normal tonsil epithe-
lium samples and corroborated the normal versus HNSCC study
of Ha et al. (2003). The Group 3 tumors were also almost exclu-Discussion
sively the only Cytokeratin 15-positive tumors as assayed by
IHC (5/6 CK15-positive tumors were in this subtype). It is inter-Head and neck squamous cell carcinomas show significant
heterogeneity in their clinical behavior that cannot presently be esting to note that the protein expression patterns of Cytokera-
tins 14 and 15 were similar in normal tonsillar epithelial samplespredicted using the current set of clinical markers; therefore,
the development of new biomarkers for survival predictions (Figures 2A and 2B) but were quite distinct in HNSCC tumors,
with most (41/47) HNSCCs being positive for Cytokeratin 14would be valuable. Previous microarray-based studies of HNSCC
have primarily focused on tumor versus normal patterns of ex- and only a handful (6/47) being positive for Cytokeratin 15. In
addition, the Group 3 tumors showed the fewest patient RFSpression (El-Naggar et al., 2002; Hwang et al., 2003; Leethanakul
et al., 2003). Others have suggested that there might be sub- events (one), which is similar to what was seen in lung carcino-
mas where the group of tumors that clustered nearest the normaltypes of HNSCC (Belbin et al., 2002); however, to date no study
has shown statistically significant differences in clinical out- lung samples showed the best outcomes (Garber et al., 2001).
The Group 4 tumors showed an expression pattern thatcomes between subtypes of HNSCC based upon gene expres-
sion patterns. Here we identified four distinct subtypes of was very similar to the pattern of gene expression induced by
exposure to cigarette smoke (Hackett et al., 2003). These dataHNSCC based upon an “intrinsic analysis” and showed that
these subtypes had differences in recurrence-free survival and suggest that the Group 4 tumors either have a sustained re-
sponse to cigarette smoke or that patients in the Group 4 sub-overall survival. These expression signatures are revealing of
the complex biology that underlies HNSCC; however, these data type are current smokers. The majority of our cohort has a heavy
smoking history (all but two were smokers); however, the timewill need to be confirmed by further research and by functional
assays. from the last cigarette smoke exposure to the time of tissue
collection was not available so we cannot determine if this isThe tumor subtype with the worst outcome was the Group
1 tumors that were characterized by the high expression of an acute or sustained response pattern. In addition, these data
suggest that there could be variations within smokers in theTGF, which is known to associate with poor clinical outcomes
in HNSCC (Endo et al., 2000; Grandis, 1998; Quon et al., 2001). ability to respond to cigarette smoke. Finally, we also profiled
four primary HNSCC-derived cell lines and saw that none ofMost HNSCC tumors express EGFR (54/56 tested here were
EGFR and see Figure 2K); however, there is additional evi- these cell lines showed the dominant patterns of expression
that defined the tumor subtypes. This finding is similar to ourdence that suggests the Group 1 tumors have an activation of
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one primary tumor, an associated lymph node metastasis was also availableearlier comparisons of breast tumors to breast cell lines where
(labeled L in Figure 1). Patient clinical information can be found in Supplemen-significant differences between cell lines and tumors were ob-
tal Table S1 (http://www.cancercell.org/cgi/content/full/5/5/489/DC1) andserved (Ross and Perou, 2001).
patient demographics are presented in Table 1. These patients were hetero-
There have been a few studies to suggest that metastases geneously treated in accordance with the standard of care dictated by their
show similar profiles to the primary tumors that they arose from disease stage. Staging and treatment planning were determined by consen-
sus of the UNC Head and Neck Tumor Board. Clinical staging (55 tumors)(Garber et al., 2001; Perou et al., 2000), suggesting that the
of the neck was determined by clinical exam and contrasted CT or MRIbiological properties of a primary tumor can reflect the proper-
imaging, while pathologic staging (38 tumors) was determined by routineties of its metastases (Ramaswamy et al., 2003). To take this
H&E staining of neck nodes in patients undergoing a neck dissection.one step farther, some have shown that the presence of metas-
We also profiled three normal tonsillar epithelium samples that were
tases at the time of surgery can be predicted based upon gene collected from three pediatric patients following routine tonsillectomy and
expression patterns present in the primary tumor (Huang et al., four HNSCC primary tumor-derived cell lines (UNC7, UMSCCA1, CAL27,
2003). The accuracy of our HNSCC “metastasis predictor” when and JHU022). Each experimental sample (tumor, normal, or cell line) was
assayed versus a common reference sample consisting of a pool of totalusing pathologically determined nodal status was approximately
RNA derived from a randomly chosen subset of 30 of the HNSCC samples.60%, but was improved to 83% when one of the four tumor
This tumor pool reference strategy has been successfully used in anothersubsites was removed from the analysis (oral cavity). Our find-
profiling study (van ’t Veer et al., 2002). In total, 78 experiments were per-
ings support the hypothesis that lymph node metastasis status formed using three separate preparations of the common reference pool.
can be predicted using the gene expression patterns of the
primary tumor. Our pathological node status predictor gene RNA preparations, labeling, and microarray hybridizations
Total RNA was purified from each sample using the Qiagen RNeasy Midiset also showed significant similarities with other microarray
Kit according to the manufacturer’s protocol (Qiagen, Valencia, CA) andanalyses of the metastatic processes in breast tumors. Namely,
25–50 milligram of tissue per sample. The integrity of the RNA was deter-we identified a likely STAT1-regulated gene cluster (Darnell,
mined using the RNA 6000 Nano LabChip Kit and an Agilent 2100 Bioanalyzer1997; Lehtonen et al., 1997; Perou et al., 1999) as being useful
(Agilent Technologies, Palo Alto, CA). Ten micrograms of total RNA were
in predicting lymph node metastasis status, as did the study of amplified per sample, using an Arcturus RiboAmp RNA Amplification kit
Huang et al. (2003), and we identified a “proliferation” signature (Arcturus, Mountain View, CA) with the following modifications. Amino-allyl-
that shared many genes with the distant recurrence predictor UTP (aa-UTP) was used in the in vitro transcription step to perform an
“indirect” labeling of the amplified RNA (aRNA). Rather than using the sup-of van ’t Veer et al. (2002). These similarities in which the high
plied IVT Master Mix as provided, we added aa-UTP into the IVT NTP mixexpression of identical genes are predicting similar behaviors
at a ratio of aa-UTP:UTP of 4:1. For indirect labeling of aRNA, 10 
g of theacross HNSCC tumors and two breast tumor data sets identifies
common reference amplified RNA (aRNA) was labeled with a Cy3 Monofunc-
common pathways and/or genes that could be playing similar tional Reactive Dye (Amersham Biosciences, UK) and 10 
g of aRNA from
roles in epithelial tumor metastasis. each experimental sample was labeled using a Cy5 Monofunctional Reactive
In summary, this work has identified a number of important Dye. The dye was quenched with 4 M hydroxylamine (Sigma, St. Louis, MO)
after a 1 hr incubation and unincorporated dye molecules were removedbiological differences among HNSCC samples that could have
using a Qia-Quick PCR Purification Kit.an impact upon clinical treatment regimens and patient out-
The labeled common reference and individual experimental samplescomes if these patterns are validated on additional cohorts. In
were combined along with 20 
g of COT-1 DNA (GIBCO-BRL), 20 
g ofparticular, we identified discriminatory patterns of expression
polyA DNA, and 20 
g of yeast tRNA and hybridized to a 12,814 gene Agilent
in our HNSCC tumors that were previously seen in microarray Human 1 cDNA microarray (Agilent Technologies). The reaction mix was
analyses of epithelial tumors of the breast and lung (Garber et hybridized on the array overnight at 65C in 3	 SSC. The microarrays were
al., 2001; Huang et al., 2003; Perou et al., 1999, 2000; Sorlie then washed using 2	 SSC/0.025% SDS, followed by 1	 SSC, and finally
a 0.2	 SSC wash. Washed arrays were quickly scanned on an Axon 4000Bet al., 2001; van ’t Veer et al., 2002), in airway tissue and tumor
Scanner. Image analysis was accomplished using GenePix Pro 4.0. The rawstudies (Ha et al., 2003; Hackett et al., 2003), and a pattern
data (.gpr files) tables were uploaded into the UNC Microarray Database,associated with activation of the EGFR pathway. The agreement
which is a mirror of the Stanford Microarray Database (Sherlock et al., 2001).
between our study and these other studies done on HNSCC and A global, linear normalization was performed to adjust the Cy3 and Cy5
different tumor sites (and done on different microarray platforms) channels (Sherlock et al., 2001). All microarray raw data tables are available at
validates the biological insights obtained here. This study, there- the UNC Microarray Database (https://genome.unc.edu/), at the supporting
website for this paper (http://dragon.med.unc.edu/pubsup/HN/), and in thefore, can serve as a central point to tie all of these studies
Gene Expression Omnibus under the accession number of GSE686 (sub-together into a common framework and has added new patterns
mitter C. Perou).and complexities. The patterns identified here should be evalu-
ated on new and independent cohorts, and if confirmed, will Statistical analysis of microarray data
represent an important new set of biomarkers for HNSCC prog- Intrinsic gene set analysis
nostication and prediction of clinical outcomes. The background subtracted, normalized log2 ratio of red over green intensity
values were first filtered to select genes that had a signal intensity of at least
Experimental procedures 1.5-fold above background in both the Cy5 and Cy3 channels. Only genes
that met these criteria in at least 80% of the 60 tissue samples were included
Patient biopsy samples and the common reference for subsequent analysis. Next, we corrected for the systematic bias that
sample for array hybridization may have been introduced by using different batches of the common refer-
Sixty fresh frozen HNSCC samples were obtained from the University of ence before further statistical analyses. We used “Distance Weighted Dis-
North Carolina at Chapel Hill (UNC) Tissue Procurement Core Facility from crimination/DWD” as described in Benito et al. (2004) on the two largest
patients undergoing surgery at the UNC Hospital and who consented to sets of samples assayed using two different batches of common reference
have their tumor tissue used for cancer research using an Institutional Review (one reference batch used only eight samples, which is too few to perform
Board approved protocol. Fifty-five tumor samples were collected from the the correction). Next, we performed an intrinsic analysis as described in
primary tumor (labeled B in Figure 1), and five tumor samples were collected Sorlie et al. (2003) by assaying spatially distinct pieces of the same tumor.
We used ten tumor pairs that were separate pieces and RNA preparationsfrom a local recurrence at the primary tumor site (labeled R in Figure 1). For
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of the same tumor, one tumor pair that was a tumor and its lymph node analysis of variance or Wilcoxon rank-sum tests (using normal scores) were
used on continuous variables to evaluate the possible difference in responsemetastasis, and designated two of the three normal tonsillar epithelia sam-
ples as a pair. Using this sample set, we searched for genes that were the across the two (or more) categories. These statistical analyses were performed
using SAS statistical software, Version 8.2, SAS Institute Inc. (Cary, NC).least variable within pairs and that were variable across different samples
by computing for each gene the average “within-pair variance” (the average Simulation analysis
The simulation was performed by randomly selecting a set of genes fromof the variance within each tumor pair) and the “between-subject variance”
(the average of the variance across all pairs not assessed for within pair the entire set of 12,814. The number randomly selected was set to the
number of genes in our subset being tested. This randomly selected setvariance). We then computed the ratio D  (within-pair variance)/(between-
subject variance) and declared those genes with the smallest values of D was then compared for overlap, with the corresponding gene sets that were
mentioned from published studies. The number of genes found in the overlapto be intrinsic. The choice of a D value cutoff was set at one standard
deviation below the average (using the “Intrinsic Gene Identifier v1.0” by was recorded and the process was repeated 10,000 times. In the final step,
the actual amount of overlap was compared between our gene sets and theMax Diehn/Stanford University). This analysis resulted in the selection of
582 clones representing 547 genes. We finally used these 582 clones to published gene sets, and this was compared to the simulated distribution.
This comparison gives the likelihood of finding co-occurrences by chance.perform a two-way average linkage hierarchical cluster analysis using the
program “Cluster” (Eisen et al., 1998) with the data being displayed relative The simulation was performed independently for each of the three gene sets
thought to have a significant overlap.to the median expression for each gene (i.e., median centering of the rows).
The cluster results were then visualized using “Treeview.”
Supervised microarray analyses Immunohistochemistry
To investigate relationships between gene expression patterns and patient- Formalin-fixed and paraffin-embedded tissue blocks from (at most) 56 tu-
associated parameters, we performed supervised analyses to identify gene mors were available for immunohistochemistry (IHC) staining. 5 
m tissue
sets that correlated with clinical parameters and then tested the ability of sections were deparaffined with xylene and dehydrated with sequential
these sets to make reliable predictions (Huang et al., 2003). In each case, washes of 100%, 95%, and 70% ethanol, and endogenous peroxidase
we utilized two different statistical methods to train a gene expression pre- activity was blocked with a 3% hydrogen peroxidase solution. For EGFR
dictor for a single parameter (e.g., lymph node metastasis status). These IHC, the tissues were digested with Proteinase K and then incubated with
methods included a K-Nearest Neighbor (KNN) metric that uses a Euclidian a rabbit polyclonal antibody against the epidermal growth factor receptor
correlation coefficient to determine the distance of a sample to its three (EGFR) using the DAKO EGFR PharmDx kit at the recommended antibody
nearest sample neighbors (Dudoit et al., 2002) and Prediction Analysis of dilution (K1494, Carpinteria, CA). The sections were next incubated with
Microarray (PAM) (Tibshirani et al., 2002). To select genes for the K-Nearest polymer labeled HRP-goat anti-mouse antibody. For other antibodies, the
Neighbor method, we used our own version of a gene selection method that samples were digested with Proteinase K and then steamed for antigen
was first described by Dudoit et al. (2002); the KNN genes were identified retrieval with citrate buffer (pH 7.0) for 30 min. The antibodies used included
in the training set according to the ratio of between-group to within-group Cytokeratin 15 (1:100 dilution, LHK15, Novocastra Laboratory Ltd, UK), Cytoker-
sums of squares (Dudoit et al., 2002). The top n ranked genes were used atin 4 (1:200, 6B10, Novocastra), Cytokeratin 14 (1:500, MS-115-P1, NeoMark-
during each round of cross validation. The size of the gene subset was ers, Fremont, CA), Desmoglein 3 (1:30, 32-6300, Zymed Laboratories, CA),
increased for subsequent rounds of CV. The set of n top-ranked genes that phosphorylated-EGFR-Tyr1173 (1:200, 44-794, Biosource, Camarillo, CA),
gave the highest average prediction accuracy during CV was also determined and Vimentin (1:50, 18-0052, Zymed). These sections were next incubated
and reported. Gene selection for PAM was completed as described in Tib- with biotin-conjugated goat anti-mouse IgG (Vector Laboratories) and then
shirani et al. (2002). strepavidin-conjugated HRP followed by the development of HRP activity
For all but one nodal predictor, we performed a 10-fold cross validation using the ABC kit and substrate (Vector Laboratories). The slides were finally
(CV) analysis to iteratively optimize the list of genes and to determine predic- counterstained with 50% hematoxylin and examined by light microscopy
tion accuracies. Each round of CV would begin by splitting the samples into on a Leica microscope at 100	 magnification. A three-point scoring system
a training set (90% of the samples) and a test set (10% left-out samples), was used where 0  invasive tumor cells present in the sample and no
with gene selection and training being performed on the 90% and then used staining seen; 1  invasive tumor cells present and weak intensity staining
to predict the status of the withheld 10%. This was repeated 10 times, each and/or 20% of cells stained; and 2  invasive tumor cells present with
time using a different 10% subset and a different gene set. Our reported strong staining in 20% of cells.
prediction accuracies are the average of these iterative cycles of prediction.
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